A hormone first identified decades ago is now at the center of a medical shift in how doctors approach diabetes and obesity. On October 11, 2024, researchers continue to focus on glucagon-like peptide-1, known as GLP-1, and its role in blood sugar control. The science behind it is not new, but its implications are still unfolding.
GLP-1 is a peptide hormone. It comes from the proglucagon peptide, a larger protein that gets broken down into smaller active pieces. The body produces GLP-1 in intestinal enteroendocrine L-cells and in certain neurons located in the brainstem. This happens after a person eats. The hormone then acts to lower blood sugar.
It does this in a specific way. GLP-1 triggers insulin secretion only when glucose levels are high. This glucose-dependent mechanism means it does not cause dangerous low blood sugar the way some older diabetes drugs can. That feature alone made it a target for drug development.
The structure of GLP-1 is precise. It contains either 30 or 31 amino acids. The initial form, called GLP-1 (1–37), goes through amidation and proteolytic cleavage. This produces two biologically active versions: GLP-1 (7–36) amide and GLP-1 (7–37). Both have a secondary structure built from two α-helices separated by a linker region. That shape allows the hormone to bind to its receptors and work on glucose metabolism.
GLP-1 belongs to a class of hormones called incretins. These are substances released from the gut that boost insulin secretion after meals. Another incretin, glucose-dependent insulinotropic peptide or GIP, does similar work. But there is a key difference. In patients with type 2 diabetes, the effect of GIP is diminished. The action of GLP-1 is preserved. That preservation made GLP-1 a valuable therapeutic target.
The insulinotropic effects of GLP-1 are well-documented. They form the basis for a class of drugs called GLP-1 receptor agonists. These medications mimic the hormone and activate its receptor. They are now used widely to treat both diabetes and obesity. The market for these drugs has grown rapidly in recent years.
But the hormone does more than stimulate insulin. Research shows GLP-1 has regulatory and protective effects on the body. The exact mechanisms and the full scope of those effects remain under study. Scientists are still working to understand how GLP-1 influences other systems beyond blood sugar control.
The history of GLP-1 research stretches back to the 1980s, when the hormone was first sequenced and its activity described. Early work focused on its role as an incretin. Later studies revealed its potential for weight loss, as it slows gastric emptying and signals satiety in the brain. That dual action on glucose and appetite drove pharmaceutical interest.
By October 2024, GLP-1 receptor agonists are among the most prescribed drugs for metabolic conditions. The medical community continues to examine how best to use them, for whom, and for how long. The hormone itself remains a subject of intense study. Its structure, its production in the gut and brainstem, and its glucose-dependent action all matter.
None of this happened overnight. It took years of basic science to map the peptide, to understand its cleavage into active forms, and to confirm its preserved action in type 2 diabetes. That foundation led to the drugs now in clinics. The story of GLP-1 is a reminder that medical breakthroughs often begin with a molecule and a question.
